Compare Ecolab Inc. (ECL) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Novavax Inc — how do they compare? Ecolab Inc. trades at $285.5 (market cap $79.73B), while Novavax Inc trades at $7.95 (market cap $1.30B). The key difference: Ecolab Inc. is far larger — about 61.3× Novavax Inc's market cap, and Ecolab Inc. pays a 1.03% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ECL | NVAX | |
|---|---|---|
Market Cap | $79.73B | $1.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $308.35 | $11.19 |
52-Week Low | $245.73 | $6.22 |
Enterprise Value | $88.51B | $879.40M |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $285.17, up 0.6% today, with a bullish technical signal and strong analyst support. The company reported Q2 2026 EPS of $2.09, beating estimates, and raised full-year guidance. Revenue growth remains steady, with a net income margin of 12.57% and robust cash flow from operations of $2.95B in 2025. Recent news highlights dividend declarations and institutional buying interest.
Outlook is positive with a consensus price target of $327.90, implying 15% upside. Risks include elevated valuation multiples and potential margin pressure from input costs. The stock's momentum is supported by earnings beats and strategic acquisitions, but investors should monitor debt levels and competitive dynamics in the water and hygiene sector.
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
